Back to today’s briefing

Story perspectives

Kazia's Paxalisib Soars 80% Amid Breast Cancer Hope

6/12/2025

42 4

Summary

Story summary

Kazia Therapeutics, hailing from Sydney, is making waves with its promising drug paxalisib in the fight against triple-negative breast cancer. After revealing encouraging preclinical results, the stock skyrocketed nearly 80%. Yet, investors must tread carefully, as financial hurdles and trial uncertainties loom. Staying alert to clinical trial updates and FDA responses is vital for savvy traders.

1 of 1

Story summary

Kazia Therapeutics, hailing from Sydney, is making waves with its promising drug paxalisib in the fight against triple-negative breast cancer. After revealing encouraging preclinical results, the stock skyrocketed nearly 80%. Yet, investors must tread carefully, as financial hurdles and trial uncertainties loom. Staying alert to clinical trial updates and FDA responses is vital for savvy traders.